452340-96-4

Usage

Uses

Used in Pharmaceutical Industry:
5-(2,2-Dimethyl-4H-benzo[d][1,3]dioxin-6-yl)oxazolidin-2-one is used as a vilanterol impurity, which is a component in the synthesis of vilanterol, a medication used for treating chronic obstructive pulmonary disease (COPD) and asthma. Its presence in the synthesis process is crucial for the development of effective treatments for these respiratory conditions.
Used in Biotechnology Industry:
5-(2,2-Dimethyl-4H-benzo[d][1,3]dioxin-6-yl)oxazolidin-2-one is used as a reagent for the preparation of a conjugate of G-protein coupled receptor binding ligand and nucleic acid molecules. This conjugate has potential applications in the development of targeted therapies and diagnostic tools, as it can help in the specific delivery of nucleic acid molecules to cells expressing the G-protein coupled receptor.

Upstream product

• 452340-95-3 tert-Butyl 2-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-6-yl)-2-hydroxyethylcarbamate 
• 68-12-2 N,N-dimethyl-formamide 
• 915132-89-7 2-amino-1-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)ethanol 

Downstream Products

• 1204187-85-8 C₂₉H₂₄⁽²⁾H₁₅NO₅ 
• 1204187-75-6 C₂₉H₂₈⁽²⁾H₁₁NO₅ 

Relevant academic research and scientific papers

SUBSTITUTED ETHANOLAMINES

The present invention relates to new substituted ethanolamine adrenergic receptor modulators, pharmaceutical compositions thereof, and methods of use thereof.

DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE β2 ADRENERGIC RECEPTOR

The present invention provides a compound of formula (I) wherein: R1 is a group selected from -CH2OH, -NHC(O)H and R2 is a hydrogen atom; or R1 together with R2 form the group -NH-C(O)-CH=CH- wherein the nitrogen atom is bound to the carbon atom in the phenyl ring holding R1 and the carbon atom is bound to the carbon atom in the phenyl ring holding R2; R3 is selected from hydrogen and halogen atoms or groups selected from -SO-R5, -SO2- R5, -NH-CO-NH2, -CO-NH2, hydantoino, C1-4alkyl, C1-4alkoxy and -SO2NR5R6; R4 is selected from hydrogen atoms, halogen atoms and C1-4alkyl groups; R5 is a C1-4alkyl group or C3-8 cycloalkyl; R6 is independently selected from hydrogen atoms and C1-4alkyl groups; n, p and q are independently 0, 1 , 2, 3 or 4; m and s are independently 0, 1 , 2 or 3; r is 0, 1 or 2; with the provisos that: at least one of m and r is not 0; the sum n+m+p+q+r+s is 7, 8, 9, 10, 11 , 12 or 13; the sum q+r+s is 2, 3, 4, 5 or 6 or a pharmaceutically-acceptable salt, solvate or stereoisomer thereof.